抗TIGIT抗体Tiragolumab单药或联合阿替利珠单抗治疗晚期实体瘤患者:1a/1b期非随机对照试验
这项1a/1b期非随机对照试验在6国13中心评估了抗TIGIT抗体Tiragolumab单药及联合阿替利珠单抗治疗晚期实体瘤的安全性和抗肿瘤活性。Tiragolumab耐受良好,未达最大耐受剂量,推荐2期剂量为600 mg每3周静脉给药;联合方案在免疫治疗初治的转移性非小细胞肺癌和食管癌中显示初步抗肿瘤活性,确认客观缓解率分别为46%(6/13)和28%(5/18)。
要点
- Tiragolumab单药或联合阿替利珠单抗耐受良好,未观察到新的安全信号。
- Tiragolumab推荐2期剂量为600 mg每3周静脉给药。
- 联合方案在免疫治疗初治转移性NSCLC确认ORR 46%(6/13),食管癌28%(5/18)。
核心结论
- Tiragolumab单药或联合阿替利珠单抗耐受良好,未观察到新的安全信号。
- 联合方案在免疫治疗初治的转移性非小细胞肺癌或食管癌患者中显示初步抗肿瘤活性。
研究设计与样本
- GO30103开放标签、首次人体1a/1b期剂量递增和剂量扩展非随机对照试验,在6国(澳大利亚、加拿大、法国、韩国、西班牙、美国)13个中心开展。
- 1a期起始日期为2016年5月23日,1b期起始日期为2016年10月11日;临床截止日期为2021年10月1日,数据分析于2022年1月24日进行。
- 患者年龄18岁及以上,基线有可测量病灶;1a期剂量递增队列n=24,1b期剂量递增队列n=49。
- 1a期患者在每个21天周期第1天接受固定剂量静脉Tiragolumab(2 mg递增至1200 mg);1b期联合固定剂量静脉阿替利珠单抗1200 mg每3周一次。
- 治疗持续至疾病进展、临床获益丧失或出现不可接受毒性。
主要发现
- 1a期和1b期剂量递增队列中位年龄分别为60岁(范围40-77)和54岁(范围25-81);女性分别为14/24(58%)和25/49(51%);既往接受4种及以上抗癌治疗者分别为10例(42%)和18例(37%)。
- 未发生剂量限制性毒性,Tiragolumab最大耐受剂量未达到(NR)。
- 最常见治疗相关不良事件:1a期为乏力(5/24,21%),1b期为瘙痒(5/49,10%);大多数不良事件为1级或2级。
- 免疫介导不良事件在1a期和1b期分别为4/24(17%)和29/49(59%),主要为1级或2级。
- Tiragolumab推荐2期剂量为600 mg每3周静脉给药,已在1b期剂量扩展中测试;1a期确认ORR为0%,1b期6%的患者(n=3)显示抗肿瘤活性证据。
关键数值与推荐
- Tiragolumab推荐2期剂量为600 mg每3周静脉给药。
- 非小细胞肺癌队列确认ORR为46%(6/13),中位DOR未达到(NR)。
- 食管癌队列确认ORR为28%(5/18),中位DOR为15.2个月(95%CI,7.0至NR)。
- 1a期确认ORR为0%;1b期6%的患者(n=3)显示抗肿瘤活性证据。
临床怎么用
- Tiragolumab单药或联合阿替利珠单抗耐受良好,未观察到新的安全信号。
- 联合方案在免疫治疗初治的转移性非小细胞肺癌或食管癌患者中显示初步抗肿瘤活性。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Inhibition of the T-cell immunoreceptor with Ig and ITIM domains (TIGIT)/poliovirus receptor pathway may amplify the antitumor immune response of atezolizumab in programmed death ligand 1-selected tumors. OBJECTIVE: To evaluate the safety and antitumor activity of the anti-TIGIT antibody tiragolumab and its combination with atezolizumab in patients with advanced solid tumors. DESIGN, SETTING, AND PARTICIPANTS: The GO30103 open-label, first-in-human phase 1a/1b dose-escalation and dose-expansion nonrandomized controlled trial was conducted at 13 sites in 6 countries (Australia, Canada, France, Korea, Spain, and the US). The start dates were May 23, 2016, for phase 1a and October 11, 2016, for phase 1b. Patients were aged 18 years or older with measurable disease at baseline. The clinical cutoff date was October 1, 2021. Data analysis was performed on January 24, 2022. INTERVENTIONS: Patients received fixed-dose intravenous tiragolumab on day 1 of each 21-day cycle (2 mg escalating to 1200 mg) in phase 1a, plus fixed-dose intravenous atezolizumab (1200 mg every 3 weeks) in phase 1b. Patients were treated until disease progression, loss of clinical benefit, or development of unacceptable toxicity. MAIN OUTCOMES AND MEASURES: The primary end points included the safety, tolerability, and recommended phase 2 dose (RP2D) of tiragolumab or combination tiragolumab plus atezolizumab. The secondary end point included the investigator-assessed objective response rate (ORR). Counts and percentages are used for categorical variables, and medians and ranges are used for continuous variables. RESULTS: Among the phase 1a (n = 24) and 1b (n = 49) dose-escalation cohorts, the median age was 60 (range, 40-77) and 54 (range, 25-81) years, respectively. More than half of patients were women (14 of 24 [58%] and 25 of 49 [51%]), and more than a third (10 [42%] and 18 [37%]) had received 4 or more prior cancer therapies. No dose-limiting toxicities occurred, and the maximum tolerated dose of tiragolumab was not reached (NR). The most frequent treatment-related adverse events (AEs) were fatigue (5 of 24 [21%]) in phase 1a and pruritus (5 of 49 [10%]) in phase 1b; the majority of AEs were grade 1 or 2. Immune-mediated AEs occurred in 4 of 24 (17%) and 29 of 49 (59%) patients during phases 1a and 1b, respectively (primarily grade 1 or 2). The RP2D of tiragolumab was 600 mg intravenously every 3 weeks, which was tested in phase 1b dose expansion. The confirmed ORR was 0% during phase 1a, with evidence of antitumor activity in 6% of patients (n = 3) during phase 1b. The safety profile of combination tiragolumab plus atezolizumab in phase 1b was similar in the dose-escalation and dose-expansion cohorts. The confirmed ORR was 46% (6 of 13) in the non-small cell lung cancer (NSCLC) cohort (median duration of response [DOR], NR) and 28% (5 of 18) in the esophageal cancer (EC) cohort (median DOR, 15.2 [95% CI, 7.0 to NR] months). CONCLUSIONS AND RELEVANCE: In this nonrandomized controlled trial, tiragolumab was well tolerated with or without atezolizumab; no new safety signals were observed. Preliminary antitumor activity was demonstrated for the combination regimen in patients with cancer immunotherapy-naive metastatic NSCLC or EC. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02794571.
引用
- Kim TW, Bedard PL, LoRusso P, et al. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial. JAMA Oncol. 2023. PMID: 37768658. doi:10.1001/jamaoncol.2023.3867
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。